share_log

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K: Novo Nordisk A/S - Share Repurchase Programme

6-K：诺和诺德-股票回购计划
美股sec公告 ·  07/22 11:16
Moomoo AI 已提取核心信息
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.
On July 22, 2024, Novo Nordisk A/S, a global healthcare leader headquartered in Denmark, reported progress on its share repurchase program. The program, which is part of a larger DKK 20 billion buyback initiative set to occur over 12 months starting February 6, 2024, saw the company repurchasing B shares amounting to DKK 2.2 billion between May 7 and August 5, 2024. Since the last update on July 15, Novo Nordisk has acquired an additional 186,967 B shares at an average price of DKK 941.45, totaling DKK 175,979,457. Overall, from the beginning of the buyback period on February 6, 2024, the company has repurchased 10,619,037 B shares at an average price of DKK 878.31 per share, amounting to DKK 9,326,780,889. These transactions have increased the company's treasury shares to 11,984,827 B shares, which is 0.3% of the share capital. Novo Nordisk's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange under the symbols 'Novo-B' and 'NVO', respectively.
2024年7月22日，总部位于丹麦的全球医疗保健领导者Novo Nordisk A / S在其股票回购计划中取得了进展。该计划是一个更大的DKk 200亿回购倡议的一部分，开始于2024年2月6日，为期12个月，公司在2024年5月7日至8月5日期间收购了价值为DKk 22亿的B类股票。自7月15日上次更新以来，Novo Nordisk已收购了额外的1869670亿股股票，平均价格为DKk 941.45，总额为DKk 175,979,457。总体而言，自2024年2月6日回购期开始以来，该公司已以每股DKk 878.31的平均价格回购了106190370亿股股票，总额达到DKk 9,326,780,889。这些交易将公司的库存股份增加到119848270亿股，占股本的0.3％。Novo Nordisk的股票在纳斯达克哥本哈根交易所和纽约证券交易所上市，分别以“Novo-B”和“NVO”为代码。
2024年7月22日，总部位于丹麦的全球医疗保健领导者Novo Nordisk A / S在其股票回购计划中取得了进展。该计划是一个更大的DKk 200亿回购倡议的一部分，开始于2024年2月6日，为期12个月，公司在2024年5月7日至8月5日期间收购了价值为DKk 22亿的B类股票。自7月15日上次更新以来，Novo Nordisk已收购了额外的1869670亿股股票，平均价格为DKk 941.45，总额为DKk 175,979,457。总体而言，自2024年2月6日回购期开始以来，该公司已以每股DKk 878.31的平均价格回购了106190370亿股股票，总额达到DKk 9,326,780,889。这些交易将公司的库存股份增加到119848270亿股，占股本的0.3％。Novo Nordisk的股票在纳斯达克哥本哈根交易所和纽约证券交易所上市，分别以“Novo-B”和“NVO”为代码。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息